These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33472742)

  • 1. Establishment of a cell processing laboratory to support hematopoietic stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy.
    Mukherjee S; Reddy O; Panch S; Stroncek D
    Transfus Apher Sci; 2021 Feb; 60(1):103066. PubMed ID: 33472742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy.
    Appelbaum JS; Milano F
    Curr Hematol Malig Rep; 2018 Dec; 13(6):484-493. PubMed ID: 30280289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical units to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
    Yakoub-Agha I
    Curr Res Transl Med; 2018 May; 66(2):57-58. PubMed ID: 29685843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concluding commentary on current trends to enhance the clinical safety of pediatric transfusion, focusing on prevention of untoward complications of HSC transplantation & newer strategies for improving the standards of safety/quality of stem cells expansion for cellular therapy.
    Sniecinski I; Seghatchian J
    Transfus Apher Sci; 2018 Jun; 57(3):378-383. PubMed ID: 29778713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor-Modified Hematopoietic Stem Cells for Cancer Therapy.
    Kao RL; Truscott LC; Chiou TT; Tsai W; Wu AM; De Oliveira SN
    Hum Gene Ther; 2019 Apr; 30(4):413-428. PubMed ID: 30860401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?
    Bouziana S; Bouzianas D
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):e183-e191. PubMed ID: 32304874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How close are we to CAR T-cell therapy for AML?
    Gill SI
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101104. PubMed ID: 31779970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.
    Kovalovsky D; Yoon JH; Cyr MG; Simon S; Voynova E; Rader C; Wiestner A; Alejo J; Pittaluga S; Gress RE
    Leukemia; 2021 Sep; 35(9):2581-2591. PubMed ID: 33633313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.
    Liu D; Badeti S; Dotti G; Jiang JG; Wang H; Dermody J; Soteropoulos P; Streck D; Birge RB; Liu C
    Cell Commun Signal; 2020 Aug; 18(1):134. PubMed ID: 32843053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing Medicaid Coverage for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy: A Project from the American Society for Transplantation and Cellular Therapy and the National Marrow Donor Program ACCESS Initiative.
    Auletta JJ; Khera N; DeMartino P; Kelkar AH; Yusuf RA; Davies SM; Knutson J; Beaver E; Maloney A; Majhail NS
    Transplant Cell Ther; 2023 Nov; 29(11):713-720. PubMed ID: 37579920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment.
    Arai Y; Choi U; Corsino CI; Koontz SM; Tajima M; Sweeney CL; Black MA; Feldman SA; Dinauer MC; Malech HL
    Mol Ther; 2018 May; 26(5):1181-1197. PubMed ID: 29622475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The making and function of CAR cells.
    Zabel M; Tauber PA; Pickl WF
    Immunol Lett; 2019 Aug; 212():53-69. PubMed ID: 31181279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.